Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant

A non-ionic surface and metformin technology, applied in the direction of medical preparations containing active ingredients, drug combinations, organic active ingredients, etc., can solve problems such as incurable and limited effectiveness of drug treatment

Inactive Publication Date: 2017-08-01
ALS MOUNTAIN +1
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although this approach has been shown to be quite successful in inhibiting the growth of HIV-1 and preventing opportunistic infections and other symptoms of AIDS, it is not a cure and the effectiveness of drug therapy may vary due to drug resistance, drug toxicity and May be limited by patient non-compliance with treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant
  • Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant
  • Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Solubility test of poloxamer 188 / 407 for aspirin in ethanol

[0092] method

[0093] (1) Prepare 0%, 10%, 20%, 30%, 40% (m / v) poloxamer 188 / 407 absolute ethanol solutions respectively, and put each solution of 10ml into 5 sealed centrifuges tube (mark accordingly on each centrifuge tube).

[0094] (2) According to the pre-test data, add an appropriate amount of aspirin into each centrifuge tube (please refer to Table 1: 0 hour data), and shake to dissolve at room temperature (30°C).

[0095] (3) Observe the centrifuge tube at each specific time interval, as shown in Table 1. When complete dissolution is observed, add 0.1 g of aspirin, then seal and continue shaking. In cases when the drug can no longer be dissolved, the previously dissolved amount of the drug can be recorded as the maximum amount required for dissolution.

[0096] (4) The solubility observation is continued until a certain amount of drug can no longer be dissolved.

[0097] (5) The observation ...

Embodiment 2

[0110] Gelation temperature measurement test

[0111] method

[0112] (1) Prepare 10 mL of temperature sensitive formulation mixture. The preparation includes equal volumes of Mixture A and Mixture B, as follows:

[0113] Each 1-mL aliquot of mixture A contains: 75 mg of metformin hydrochloride; 5 mg of serotonin-creatinine sulfate complex; 68.75 mg of poloxamer 407; 18.75 mg of poloxamer 188; 0.5 mg of sodium metabisulfite; and water for injection to a total volume of 1 mL. Each 1-mL aliquot of mixture B contained: 200 mg of aspirin; 450 mg of poloxamer 407; 5 mg of tartaric acid; and absolute ethanol added to a total volume of 1 mL.

[0114] (2) The drug mixture is then added to a 25-mL serum bottle (with stir bar).

[0115] (3) Put the serum bottle in a water bath at 28° C. for 15 minutes.

[0116] (4) When stirring is started, it can be observed whether the stirring bar can rotate. When the stirring bar stops rotating, the previous gel temperature can be recorded...

Embodiment 3

[0127] Dissolution release test

[0128] method

[0129] (1) Prepare 10 mL of formulation solution. Prepare this formulation solution according to the following instructions: Prepare a 10-mL solution containing equal volumes of Mixture A and Mixture B. Each 1-mL aliquot of mixture A contains: 75 mg of metformin hydrochloride; 5 mg of serotonin-creatinine sulfate complex; 68.75 mg of poloxamer 407; 18.75 mg of poloxamer 188; 0.5 mg of sodium metabisulfite; and water for injection to a total volume of 1 mL. Each 1-mL aliquot of mixture B contained: 200 mg of aspirin; 450 mg of poloxamer 407; 5 mg of tartaric acid; and absolute ethanol added to a total volume of 1 mL.

[0130] (2) Then slowly add the solution into 15-mL centrifuge tubes (3 mL per tube), to ensure that no solution gets stuck on the wall of the test tube, and at the same time keep the liquid level of each tube at the same height.

[0131] (3) Place the test tube in a 37°C cell culture incubator for 30 minut...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1 ) a therapeutically effective quantity of a first agent that is Metformin or a salt thereof; (2) a therapeutically effective quantity of a second agent that is Aspirin; (3) a therapeutically effective quantity of a third agent that serotonin creatinine sulfate complex; (4) a non-ionic surfactant; and (5) a solvent that is a lower alkanol. A preferred composition comprises metformin hydrochloride, aspirin, and serotonin creatinine sulfate complex for the first, second, and third agents. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.

Description

[0001] Cross References to Related Applications [0002] This application claims the rights and interests of Chen Jianhong's U.S. Provisional Patent Application Serial No. 62 / 058,150, entitled "Pharmaceutical Composition Containing Aspirin, Metformin, and Serotonin and Nonionic Surfactant", filed on October 1, 2014, Its contents are incorporated herein by reference. technical field [0003] The present invention relates to a pharmaceutical preparation comprising a first medicament, a second medicament, a third medicament, a solvent and at least one non-ionic surfactant, and to the use of these pharmaceutical compositions for various diseases and conditions. Background technique [0004] Metabolic syndrome is characterized by a cluster of metabolic risk factors including abdominal obesity, atherosclerotic dyslipidemia (eg, high triglycerides, low HDL cholesterol, and high LDL cholesterol), hypertension, insulin resistance , prothrombotic state (e.g., high fibrinogenor plasmi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/52
CPCA61K31/155A61K31/4045A61K9/0019A61K47/10A61K31/616A61P43/00A61P3/10A61K2300/00A61K47/34
Inventor 陈建宏
Owner ALS MOUNTAIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap